Mirati Therapeutics (BOVESPA:M2RT34) - Cotización, noticias y análisis

Resumen de acción M2RT34

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States.

Acerca de la empresa

M2RT34 fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Recompensas

Cotiza un 77.7% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 42.24%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de Mirati Therapeutics, Inc.

Blau Farmacêutica

BOVESPA:BLAU3

R$1.9b

Biomm

BOVESPA:BIOM3

R$1.4b

Hypera

BOVESPA:HYPE3

R$18.1b

Ultragenyx Pharmaceutical

NasdaqGS:RARE

US$3.7b

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Mirati Therapeutics
Historical stock prices
Current Share Price	US$19.46
52 Week High	US$21.64
52 Week Low	US$9.00
Beta	0.77
1 Month Change	1.35%
3 Month Change	4.96%
1 Year Change	28.96%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-54.84%

Noticias y actualizaciones recientes

Recent updates

Rentabilidad de los accionistas

	M2RT34	BR Biotechs	Mercado BR
7D	0.6%	0.8%	0.9%
1Y	29.0%	-6.0%	15.0%

Rentabilidad vs. Industria: M2RT34 superó al sector BR Biotechs , que obtuvo un rendimiento del -9% el año pasado.

Rentabilidad vs. Mercado: M2RT34 superó al mercado BR, que obtuvo un rendimiento del 13.1% el año pasado.

Volatilidad de los precios

Is M2RT34's price volatile compared to industry and market?
M2RT34 volatility
M2RT34 Average Weekly Movement	1.7%
Biotechs Industry Average Movement	9.5%
Market Average Movement	4.7%
10% most volatile stocks in BR Market	8.8%
10% least volatile stocks in BR Market	2.3%

Precio estable de las acciones: M2RT34 no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: Datos insuficientes para determinar el cambio de volatilidad de M2RT34 en el último año.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1995	587	Chuck Baum	www.mirati.com

Resumen de fundamentos de Mirati Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de Mirati Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de M2RT34
Capitalización bursátil	R$20.53b
Beneficios(TTM)	-R$3.62b
Ingresos (TTM)	R$190.40m

107.8x

Ratio precio-ventas (PS)

-5.7x

Ratio precio-beneficio (PE)

¿Está M2RT34 sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de M2RT34
Ingresos	US$38.19m
Coste de los ingresos	US$510.48m
Beneficio bruto	-US$472.29m
Otros gastos	US$253.59m
Beneficios	-US$725.88m

Últimos beneficios comunicados

Sep 30, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-10.35
Margen bruto	-1,236.66%
Margen de beneficio neto	-1,900.65%
Ratio deuda/patrimonio	0%

¿Cómo se ha desempeñado M2RT34 a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción M2RT34

Recompensas

Análisis de riesgos

Competidores de Mirati Therapeutics, Inc.

BOVESPA:BLAU3

R$1.9b

BOVESPA:BIOM3

R$1.4b

BOVESPA:HYPE3

R$18.1b

NasdaqGS:RARE

US$3.7b

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Recent updates

Mirati Therapeutics, Inc. Files Form 15

Mirati Therapeutics, Inc.(NasdaqGS:MRTX) dropped from NASDAQ Biotechnology Index

Bristol-Myers Squibb Company (NYSE:BMY) completed the acquisition of Mirati Therapeutics, Inc. (NasdaqGS:MRTX) from a group of shareholders.

Mirati Therapeutics, Inc. Receives Positive Opinion from CHMP for KRAZATI as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer with a KRASG12C Mutation Following a Re-Examination Procedure

Mirati Therapeutics, Inc. Presents Late-Breaking Results Evaluating the Combination of Adagrasib and Pembrolizumab in First-Line Non-Small Cell Lung Cancer

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Bristol-Myers Squibb Company (NYSE:BMY) entered into a definitive agreement to acquire Mirati Therapeutics, Inc. (NasdaqGS:MRTX) for $3.4 billion.

Sanofi Reportedly Explores Potential Acquisition of Mirati Therapeutics

Mirati Therapeutics, Inc. Announces CFO Changes Effective as of September 8, 2023

Mirati Therapeutics, Inc. Publishes Preclinical and Initial Clinical Data for MRTX1719 to Treat MTAP-Deleted Cancers Through Novel Approach to MTA-Cooperative PRMT5 Inhibition

Mirati Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Mirati Therapeutics Provides Update on Regulatory Review in the European Union of Krazati (Adagrasib) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with A Krasg12c Mutation

Mirati Therapeutics Appoints Carol Gallagher, Pharm.D. as New Independent Director

Mirati Therapeutics Provides Update on the Phase 3 SAPPHIRE Study Evaluating Sitravatinib in Combination with OPDIVO(R)

Mirati Therapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Mirati Therapeutics, Inc. Announces U.S. Food and Drug Administration Clears the Investigational New Drug (Ind) Application of MRTX1133

Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

Mirati Therapeutics, Inc. Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

Mirati Therapeutics, Inc. Announces Update for the Phase 3 SAPPHIRE Study

Mirati Therapeutics Reportedly Seen as Takeover Target Once Again

Mirati Therapeutics, Inc. Announces Management Changes

Mirati Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Mirati Therapeutics, Inc. Presents Late-Breaking Adagrasib Monotherapy and Combination

Mirati Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Mirati Therapeutics, Inc. Announces Results of A Prospective Analysis from the Phase 1B Cohort of the KRYSTAL-1

Mirati Therapeutics Announces Investigational Adagrasib Delivers Positive Results in Registration-Enabling Study of Patients with KRASG12C-Mutated Advanced Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. Submits Marketing Authorization Application to the European Medicines Agency for Investigational adagrasib as a Treatment

Mirati Therapeutics Appoints Laurie Stelzer as Chief Financial Officer

Mirati Therapeutics, Inc. to Present New Research at the 2022 ASCO Annual Meeting Showcasing Clinical Advances of Treating KRASG12C-Mutated Lung Cancer with Investigational Adagrasib

Mirati Therapeutics, Inc. to Report Q1, 2022 Results on May 04, 2022

Mirati Therapeutics, Inc., Annual General Meeting, May 12, 2022

U.S. Food and Drug Administration Accepts New Drug Application for Adagrasib as Treatment of Previously Treated Krasg12c-Mutated Non-Small Cell Lung Cancer

Mirati Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Rentabilidad de los accionistas

Volatilidad de los precios

Acerca de la empresa

Resumen de fundamentos de Mirati Therapeutics, Inc.

107.8x

-5.7x

Beneficios e Ingresos